{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:31:15Z","timestamp":1793154675281,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00702-025-03070-3","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T11:07:48Z","timestamp":1764846468000},"page":"853-864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neurofilament light chain as a diagnostic and prognostic biomarker in atypical parkinsonisms: current evidence, new data, challenges, and future directions"],"prefix":"10.1007","volume":"133","author":[{"given":"A.","family":"Perez-Soriano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Painous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Perez-Montesino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"de Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Camara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Compta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"3070_CR1","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.neurobiolaging.2006.03.010","volume":"28","author":"WF Abdo","year":"2007","unstructured":"Abdo WF, Bloem BR, Van Geel WJ et al (2007) CSF neurofilament light chain and Tau differentiate multiple system atrophy from parkinson\u2019s disease. Neurobiol Aging 28:742\u2013747. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2006.03.010","journal-title":"Neurobiol Aging"},{"key":"3070_CR2","doi-asserted-by":"publisher","first-page":"awac328","DOI":"10.1093\/BRAIN\/AWAC328","volume":"146","author":"S Abu-Rumeileh","year":"2022","unstructured":"Abu-Rumeileh S, Abdelhak A, Foschi M et al (2022) The multifaceted role of neurofilament light chain protein in non-primary neurological diseases. Brain 146:awac328. https:\/\/doi.org\/10.1093\/BRAIN\/AWAC328","journal-title":"Brain"},{"key":"3070_CR3","doi-asserted-by":"publisher","first-page":"e000143","DOI":"10.1136\/bmjno-2021-000143","volume":"3","author":"J Alagaratnam","year":"2021","unstructured":"Alagaratnam J, von Widekind S, De Francesco D et al (2021) Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis. BMJ Neurol Open 3:e000143. https:\/\/doi.org\/10.1136\/bmjno-2021-000143","journal-title":"BMJ Neurol Open"},{"key":"3070_CR80","unstructured":"Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy - Alterity Therapeutics https:\/\/alteritytherapeutics.com\/investor-centre\/news\/2025\/07\/28\/alterity-therapeutics-reports-positive-topline-data-from-open-label-phase-2-clinical-trial-of-ath434-in-multiple-system-atrophy\/. Accessed 5 Sep 2025b"},{"key":"3070_CR4","doi-asserted-by":"publisher","first-page":"E867","DOI":"10.1212\/CPJ.0000000000001116","volume":"11","author":"E Angelopoulou","year":"2021","unstructured":"Angelopoulou E, Bougea A, Papadopoulos A et al (2021) CSF and Circulating NfL as biomarkers for the discrimination of Parkinson disease from atypical parkinsonian syndromes: meta-analysis. Neurol Clin Pract 11:E867\u2013E875. https:\/\/doi.org\/10.1212\/CPJ.0000000000001116","journal-title":"Neurol Clin Pract"},{"key":"3070_CR5","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1515\/CCLM-2023-0036","volume":"61","author":"B Arslan","year":"2023","unstructured":"Arslan B, Zetterberg H (2023) Neurofilament light chain as neuronal injury marker - What is needed to facilitate implementation in clinical laboratory practice? Clin Chem Lab Med 61:1140\u20131149. https:\/\/doi.org\/10.1515\/CCLM-2023-0036\/ASSET\/GRAPHIC\/J_CCLM-2023-0036_FIG_004.JPG.","journal-title":"Clin Chem Lab Med"},{"key":"3070_CR6","doi-asserted-by":"publisher","unstructured":"Ashton NJ, Janelidze S, Al Khleifat A et al (2021) A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun 12. https:\/\/doi.org\/10.1038\/S41467-021-23620-Z","DOI":"10.1038\/S41467-021-23620-Z"},{"key":"3070_CR7","doi-asserted-by":"publisher","unstructured":"Baiardi S, Rossi M, Giannini G et al (2025) Head-to-head comparison of four cerebrospinal fluid and three plasma neurofilament light chain assays in parkinsonism. NPJ Parkinsons Dis 11. https:\/\/doi.org\/10.1038\/S41531-025-00951-Y","DOI":"10.1038\/S41531-025-00951-Y"},{"key":"3070_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/bs.mie.2015.07.009","volume":"569","author":"P Bomont","year":"2016","unstructured":"Bomont P (2016) Degradation of the intermediate filament family by gigaxonin. Methods Enzymol 569:215\u2013231. https:\/\/doi.org\/10.1016\/bs.mie.2015.07.009","journal-title":"Methods Enzymol"},{"key":"3070_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/J.CEB.2020.10.011","volume":"68","author":"P Bomont","year":"2021","unstructured":"Bomont P (2021) The dazzling rise of neurofilaments: physiological functions and roles as biomarkers. Curr Opin Cell Biol 68:181\u2013191. https:\/\/doi.org\/10.1016\/J.CEB.2020.10.011","journal-title":"Curr Opin Cell Biol"},{"key":"3070_CR10","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/S00702-025-02930-2","volume":"132","author":"A Bougea","year":"2025","unstructured":"Bougea A, Colosimo C, Falup-Pecurariu C et al (2025) Fluid biomarkers in atypical parkinsonism: current state and future perspectives. J Neural Transm 132:921\u2013941. https:\/\/doi.org\/10.1007\/S00702-025-02930-2","journal-title":"J Neural Transm"},{"key":"3070_CR11","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","volume":"13","author":"AL Boxer","year":"2014","unstructured":"Boxer AL, Lang AE, Grossman M et al (2014) Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial. Lancet Neurol 13:676\u2013685. https:\/\/doi.org\/10.1016\/S1474-4422(14)70088-2","journal-title":"Lancet Neurol"},{"key":"3070_CR12","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/JAMANEUROL.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel C, Van Wieringen WN, Zetterberg H et al (2019) Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol 76:1035. https:\/\/doi.org\/10.1001\/JAMANEUROL.2019.1534","journal-title":"JAMA Neurol"},{"key":"3070_CR13","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/MDS.29784","volume":"39","author":"L Buur","year":"2024","unstructured":"Buur L, Wiedemann J, Larsen F et al (2024) Randomized phase I trial of the \u03b1-Synuclein antibody Lu AF82422. Mov Disord 39:936\u2013944. https:\/\/doi.org\/10.1002\/MDS.29784","journal-title":"Mov Disord"},{"key":"3070_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/J.1365-2990.2007.00926.X","volume":"34","author":"RO Carare","year":"2008","unstructured":"Carare RO, Bernardes-Silva M, Newman TA et al (2008) Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol 34:131\u2013144. https:\/\/doi.org\/10.1111\/J.1365-2990.2007.00926.X","journal-title":"Neuropathol Appl Neurobiol"},{"key":"3070_CR15","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1093\/BRAIN\/AWAC253","volume":"145","author":"V Chelban","year":"2022","unstructured":"Chelban V, Nikram E, Perez-Soriano A et al (2022) Neurofilament light levels predict clinical progression and death in multiple system atrophy. Brain 145:4398\u20134408. https:\/\/doi.org\/10.1093\/BRAIN\/AWAC253","journal-title":"Brain"},{"key":"3070_CR16","doi-asserted-by":"publisher","first-page":"119975","DOI":"10.1016\/J.CCA.2024.119975","volume":"565","author":"Y Chen","year":"2025","unstructured":"Chen Y, Huang J, Li Y et al (2025) Diagnostic value of six plasma biomarkers in progressive supranuclear palsy, multiple system atrophy, and parkinson\u2019s disease. Clin Chim Acta 565:119975. https:\/\/doi.org\/10.1016\/J.CCA.2024.119975","journal-title":"Clin Chim Acta"},{"key":"3070_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/J.PARKRELDIS.2022.05.006","volume":"99","author":"Y Compta","year":"2022","unstructured":"Compta Y, Painous C, Soto M et al (2022) Combined CSF \u03b1-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: from bedside to bench, and back again. Parkinsonism Relat Disord 99:33\u201341. https:\/\/doi.org\/10.1016\/J.PARKRELDIS.2022.05.006","journal-title":"Parkinsonism Relat Disord"},{"key":"3070_CR18","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1007\/S00415-020-09781-9","volume":"268","author":"S Cong","year":"2021","unstructured":"Cong S, Xiang C, Wang H, Cong S (2021) Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis. J Neurol 268:2703\u20132712. https:\/\/doi.org\/10.1007\/S00415-020-09781-9","journal-title":"J Neurol"},{"key":"3070_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/ANE.13116","volume":"140","author":"R Constantinescu","year":"2019","unstructured":"Constantinescu R, Rosengren L, Eriksson B et al (2019) Cerebrospinal fluid neurofilament light and Tau protein as mortality biomarkers in parkinsonism. Acta Neurol Scand 140:147\u2013156. https:\/\/doi.org\/10.1111\/ANE.13116","journal-title":"Acta Neurol Scand"},{"key":"3070_CR20","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/S41591-021-01455-X","volume":"27","author":"T Dam","year":"2021","unstructured":"Dam T, Boxer AL, Golbe LI et al (2021) Safety and efficacy of anti-tau monoclonal antibody Gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med 27:1451\u20131457. https:\/\/doi.org\/10.1038\/S41591-021-01455-X","journal-title":"Nat Med"},{"key":"3070_CR21","doi-asserted-by":"publisher","unstructured":"Delaby C, Ladang A, Martinez-Yriarte J et al (2025) Clinical use and reporting of neurofilament quantification in neurological disorders: a global overview. Alzheimer\u2019s Dement 21. https:\/\/doi.org\/10.1002\/alz.70343","DOI":"10.1002\/alz.70343"},{"key":"3070_CR22","doi-asserted-by":"publisher","unstructured":"Demiri S, Veltsista D, Siokas V et al (2025) Neurofilament light chain in cerebrospinal fluid and blood in multiple system atrophy: a systematic review and meta-analysis. Brain Sci 15. https:\/\/doi.org\/10.3390\/BRAINSCI15030241","DOI":"10.3390\/BRAINSCI15030241"},{"key":"3070_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4103\/AIAN.AIAN_507_23","volume":"27","author":"S Dey","year":"2024","unstructured":"Dey S, Yelamanchi R, Mullapudi T et al (2024) Association of Insulin-like growth Factor-1 and neurofilament light chain in patients with progressive supranuclear palsy. Ann Indian Acad Neurol 27:40\u201345. https:\/\/doi.org\/10.4103\/AIAN.AIAN_507_23","journal-title":"Ann Indian Acad Neurol"},{"key":"3070_CR24","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ANA.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P et al (2017) Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol 81:857. https:\/\/doi.org\/10.1002\/ANA.24954","journal-title":"Ann Neurol"},{"key":"3070_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/MDS.22732","volume":"25","author":"R Dodel","year":"2010","unstructured":"Dodel R, Spottke A, Gerhard A et al (2010) Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [11\u00a0C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 25:97\u2013107. https:\/\/doi.org\/10.1002\/MDS.22732","journal-title":"Mov Disord"},{"key":"3070_CR26","doi-asserted-by":"publisher","unstructured":"Dong J, Ueda H (2017) ELISA-type assays of trace biomarkers using microfluidic methods. Wiley Interdiscip Rev Nanomed Nanobiotechnol 9. https:\/\/doi.org\/10.1002\/WNAN.1457","DOI":"10.1002\/WNAN.1457"},{"key":"3070_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.parkreldis.2018.06.018","volume":"56","author":"L Donker Kaat","year":"2018","unstructured":"Donker Kaat L, Meeter LH, Chiu WZ et al (2018) Serum neurofilament light chain in progressive supranuclear palsy. Parkinsonism Relat Disord 56:98\u2013101. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.06.018","journal-title":"Parkinsonism Relat Disord"},{"key":"3070_CR28","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1016\/j.parkreldis.2015.09.038","volume":"22","author":"S Eschlb\u00f6ck","year":"2016","unstructured":"Eschlb\u00f6ck S, Krismer F, Wenning GK (2016) Interventional trials in atypical parkinsonism. Parkinsonism Relat Disord 22:S82\u2013S92. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.09.038","journal-title":"Parkinsonism Relat Disord"},{"key":"3070_CR79","unstructured":"Food and Drug Administration (2023) FDA approves treatment of amyotrophic lateral sclerosis associated with mutation in SOD1 gene. FDA. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene. Accessed 29 September 2025"},{"key":"3070_CR29","doi-asserted-by":"publisher","unstructured":"Gafson AR, Barth\u00e9lemy NR, Bomont P et al (2020) Neurofilaments: neurobiological foundations for biomarker applications. Brain 143:1975. https:\/\/doi.org\/10.1093\/BRAIN\/AWAA098","DOI":"10.1093\/BRAIN\/AWAA098"},{"key":"3070_CR30","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1093\/BRAIN\/AWM032","volume":"130","author":"LI Golbe","year":"2007","unstructured":"Golbe LI, Ohman-Strickland PA (2007) A clinical rating scale for progressive supranuclear palsy. Brain 130:1552\u20131565. https:\/\/doi.org\/10.1093\/BRAIN\/AWM032","journal-title":"Brain"},{"key":"3070_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/S41531-023-00481-5","volume":"9","author":"Y Guo","year":"2023","unstructured":"Guo Y, Shen XN, Huang SY et al (2023) Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy. NPJ Parkinsons Dis 9:40. https:\/\/doi.org\/10.1038\/S41531-023-00481-5","journal-title":"NPJ Parkinsons Dis"},{"key":"3070_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-31517-z","volume":"8","author":"S Hall","year":"2018","unstructured":"Hall S, Janelidze S, Surova Y et al (2018) Cerebrospinal fluid concentrations of inflammatory markers in parkinson\u2019s disease and atypical parkinsonian disorders. Sci Rep 2018 8:1. https:\/\/doi.org\/10.1038\/s41598-018-31517-z","journal-title":"Sci Rep 2018"},{"key":"3070_CR33","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","volume":"88","author":"O Hansson","year":"2017","unstructured":"Hansson O, Janelidze S, Hall S et al (2017) Blood-based nfl: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 88:930\u2013937. https:\/\/doi.org\/10.1212\/WNL.0000000000003680","journal-title":"Neurology"},{"key":"3070_CR35","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32:853\u2013864. https:\/\/doi.org\/10.1002\/mds.26987","journal-title":"Mov Disord"},{"key":"3070_CR34","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S1474-4422(20)30489-0","volume":"20","author":"GU H\u00f6glinger","year":"2021","unstructured":"H\u00f6glinger GU, Litvan I, Mendonca N et al (2021) Safety and efficacy of Tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol 20:182\u2013192. https:\/\/doi.org\/10.1016\/S1474-4422(20)30489-0","journal-title":"Lancet Neurol"},{"key":"3070_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/MDS.870130116","volume":"13","author":"B Holmberg","year":"1998","unstructured":"Holmberg B, Rosengren L, Karlsson JE, Johnels B (1998) Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with parkinson\u2019s disease. Mov Disord 13:70\u201377. https:\/\/doi.org\/10.1002\/MDS.870130116","journal-title":"Mov Disord"},{"key":"3070_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1353-8020(00)00083-3","volume":"8","author":"B Holmberg","year":"2001","unstructured":"Holmberg B, Johnels B, Ingvarsson P et al (2001) CSF-neurofilament and Levodopa tests combined with discriminant analysis May contribute to the differential diagnosis of parkinsonian syndromes. Parkinsonism Relat Disord 8:23\u201331. https:\/\/doi.org\/10.1016\/S1353-8020(00)00083-3","journal-title":"Parkinsonism Relat Disord"},{"key":"3070_CR39","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/JNNP-2017-315857","volume":"88","author":"E Jabbari","year":"2017","unstructured":"Jabbari E, Zetterberg H, Morris HR (2017) Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. J Neurol Neurosurg Psychiatr 88:883\u2013888. https:\/\/doi.org\/10.1136\/JNNP-2017-315857","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3070_CR38","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/JNNP-2018-320151","volume":"90","author":"E Jabbari","year":"2019","unstructured":"Jabbari E, Woodside J, Guo T et al (2019) Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatr 90:768\u2013773. https:\/\/doi.org\/10.1136\/JNNP-2018-320151","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3070_CR40","doi-asserted-by":"publisher","first-page":"6991","DOI":"10.1007\/S00415-024-12647-Z","volume":"271","author":"S Katzdobler","year":"2024","unstructured":"Katzdobler S, N\u00fcbling G, Klietz M et al (2024) GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA). J Neurol 271:6991. https:\/\/doi.org\/10.1007\/S00415-024-12647-Z","journal-title":"J Neurol"},{"key":"3070_CR41","doi-asserted-by":"publisher","unstructured":"Khalil M, Pirpamer L, Hofer E et al (2020) Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun 11. https:\/\/doi.org\/10.1038\/S41467-020-14612-6","DOI":"10.1038\/S41467-020-14612-6"},{"key":"3070_CR42","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/S41582-024-00955-X","volume":"20","author":"M Khalil","year":"2024","unstructured":"Khalil M, Teunissen CE, Lehmann S et al (2024) Neurofilaments as biomarkers in neurological disorders \u2014 towards clinical application. Nat Rev Neurol 20:269\u2013287. https:\/\/doi.org\/10.1038\/S41582-024-00955-X","journal-title":"Nat Rev Neurol"},{"key":"3070_CR43","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/JNC.15944","volume":"167","author":"D Kon\u00ed\u010dkov\u00e1","year":"2023","unstructured":"Kon\u00ed\u010dkov\u00e1 D, Men\u0161\u00edkov\u00e1 K, Kl\u00ed\u010dov\u00e1 K et al (2023) Cerebrospinal fluid and blood serum biomarkers in neurodegenerative proteinopathies: a prospective, open, cross-correlation study. J Neurochem 167:168\u2013182. https:\/\/doi.org\/10.1111\/JNC.15944","journal-title":"J Neurochem"},{"key":"3070_CR44","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1161\/STROKEAHA.119.024941","volume":"50","author":"FK Korley","year":"2019","unstructured":"Korley FK, Goldstick J, Mastali M et al (2019) Serum NfL (Neurofilament light Chain) levels and incident stroke in adults with diabetes mellitus. Stroke 50:1669\u20131675. https:\/\/doi.org\/10.1161\/STROKEAHA.119.024941","journal-title":"Stroke"},{"key":"3070_CR45","doi-asserted-by":"publisher","unstructured":"Kou W, Li S, Yan R et al (2025) Cerebrospinal fluid and blood neurofilament light chain in parkinson\u2019s disease and atypical parkinsonian syndromes: a systematic review and bayesian network meta-analysis. J Neurol 272. https:\/\/doi.org\/10.1007\/S00415-025-13051-X","DOI":"10.1007\/S00415-025-13051-X"},{"key":"3070_CR46","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/CCLM-2015-1195","volume":"54","author":"J Kuhle","year":"2016","unstructured":"Kuhle J, Barro C, Andreasson U et al (2016) Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 54:1655\u20131661. https:\/\/doi.org\/10.1515\/CCLM-2015-1195","journal-title":"Clin Chem Lab Med"},{"key":"3070_CR47","doi-asserted-by":"publisher","first-page":"e1104","DOI":"10.1212\/WNL.0000000000008088","volume":"93","author":"CH Lin","year":"2019","unstructured":"Lin CH, Li CH, Yang KC et al (2019) Blood nfl: A biomarker for disease severity and progression in Parkinson disease. Neurology 93:e1104\u2013e1111. https:\/\/doi.org\/10.1212\/WNL.0000000000008088","journal-title":"Neurology"},{"key":"3070_CR48","doi-asserted-by":"publisher","unstructured":"Liu M, Cai Y, Pan J et al (2024) Serum neurofilament light chain as a diagnostic and prognostic biomarker in multiple system atrophy: a prospective cohort study. J Neurol 272. https:\/\/doi.org\/10.1007\/S00415-024-12784-5","DOI":"10.1007\/S00415-024-12784-5"},{"key":"3070_CR49","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1136\/JNNP-2014-309562","volume":"86","author":"NK Magdalinou","year":"2015","unstructured":"Magdalinou NK, Paterson RW, Schott JM et al (2015) A panel of nine cerebrospinal fluid biomarkers May identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatr 86:1240\u20131247. https:\/\/doi.org\/10.1136\/JNNP-2014-309562","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3070_CR50","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/mdc3.12454","volume":"4","author":"N Malek","year":"2017","unstructured":"Malek N, Lawton MA, Grosset KA et al (2017) Autonomic dysfunction in early parkinson\u2019s disease: results from the united Kingdom tracking parkinson\u2019s study. Mov Disord Clin Pract 4:509\u2013516. https:\/\/doi.org\/10.1002\/mdc3.12454","journal-title":"Mov Disord Clin Pract"},{"key":"3070_CR51","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.parkreldis.2020.05.033","volume":"77","author":"S Mangesius","year":"2020","unstructured":"Mangesius S, Mariotto S, Ferrari S et al (2020) Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. Parkinsonism Relat Disord 77:57\u201363. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.05.033","journal-title":"Parkinsonism Relat Disord"},{"key":"3070_CR52","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ACN3.50972","volume":"7","author":"A Manouchehrinia","year":"2020","unstructured":"Manouchehrinia A, Piehl F, Hillert J et al (2020) Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Ann Clin Transl Neurol 7:139\u2013143. https:\/\/doi.org\/10.1002\/ACN3.50972","journal-title":"Ann Clin Transl Neurol"},{"key":"3070_CR53","doi-asserted-by":"publisher","unstructured":"Marotta C, Sinclair B, O\u2019Brien TJ, Vivash L (2025) Biomarkers of disease progression in progressive supranuclear palsy for use in clinical trials. Brain Commun 7. https:\/\/doi.org\/10.1093\/BRAINCOMMS\/FCAF022","DOI":"10.1093\/BRAINCOMMS\/FCAF022"},{"key":"3070_CR54","doi-asserted-by":"publisher","first-page":"E1479","DOI":"10.1212\/WNL.0000000000007179","volume":"92","author":"TM Marques","year":"2019","unstructured":"Marques TM, Van Rumund A, Oeckl P et al (2019) Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology 92:E1479\u2013E1486. https:\/\/doi.org\/10.1212\/WNL.0000000000007179","journal-title":"Neurology"},{"key":"3070_CR55","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1055\/s-0037-1602422","volume":"37","author":"N McFarland","year":"2017","unstructured":"McFarland N, Hess C (2017) Recognizing atypical parkinsonisms: red flags and therapeutic approaches. Semin Neurol 37:215\u2013227. https:\/\/doi.org\/10.1055\/s-0037-1602422","journal-title":"Semin Neurol"},{"key":"3070_CR56","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3390\/CELLS9020358","volume":"9","author":"DC Mu\u00f1oz-Lasso","year":"2020","unstructured":"Mu\u00f1oz-Lasso DC, Rom\u00e1-Mateo C, Pallard\u00f3 FV, Gonzalez-Cabo P (2020) Much more than a scaffold: cytoskeletal proteins in neurological disorders. Cells 9:358. https:\/\/doi.org\/10.3390\/CELLS9020358","journal-title":"Cells"},{"key":"3070_CR57","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/MDS.29324","volume":"38","author":"D Oender","year":"2023","unstructured":"Oender D, Faber J, Wilke C et al (2023) Evolution of clinical outcome measures and biomarkers in sporadic adult-onset degenerative ataxia. Mov Disord 38:654\u2013664. https:\/\/doi.org\/10.1002\/MDS.29324","journal-title":"Mov Disord"},{"key":"3070_CR58","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.1007\/S00415-023-11741-Y\/METRICS","volume":"270","author":"L Peng","year":"2023","unstructured":"Peng L, Wan L, Liu M et al (2023) Diagnostic and prognostic performance of plasma neurofilament light chain in multiple system atrophy: a cross-sectional and longitudinal study. J Neurol 270:4248\u20134261. https:\/\/doi.org\/10.1007\/S00415-023-11741-Y\/METRICS","journal-title":"J Neurol"},{"key":"3070_CR59","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jim.2009.09.014","volume":"352","author":"A Petzold","year":"2010","unstructured":"Petzold A, Altintas A, Andreoni L et al (2010) Neurofilament ELISA validation. J Immunol Methods 352:23\u201331. https:\/\/doi.org\/10.1016\/j.jim.2009.09.014","journal-title":"J Immunol Methods"},{"key":"3070_CR60","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1474-4422(14)70288-1","volume":"14","author":"W Poewe","year":"2015","unstructured":"Poewe W, Seppi K, Fitzer-Attas CJ et al (2015) Efficacy of Rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurol 14:145\u2013152. https:\/\/doi.org\/10.1016\/S1474-4422(14)70288-1","journal-title":"Lancet Neurol"},{"key":"3070_CR61","doi-asserted-by":"publisher","first-page":"e43595","DOI":"10.1371\/journal.pone.0043595","volume":"7","author":"JA Potashkin","year":"2012","unstructured":"Potashkin JA, Santiago JA, Ravina BM et al (2012) Biosignatures for parkinson\u2019s disease and atypical parkinsonian disorders patients. PLoS ONE 7:e43595. https:\/\/doi.org\/10.1371\/journal.pone.0043595","journal-title":"PLoS ONE"},{"issue":"1 7","key":"3070_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-021-00232-4","volume":"7","author":"C Quadalti","year":"2021","unstructured":"Quadalti C, Calandra-Buonaura G, Baiardi S et al (2021) Neurofilament light chain and \u03b1-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes. Npj Parkinson\u2019s Disease 2021 7(1 7):1\u20138. https:\/\/doi.org\/10.1038\/s41531-021-00232-4","journal-title":"Npj Parkinson\u2019s Disease 2021"},{"key":"3070_CR64","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ACN3.290","volume":"3","author":"JC Rojas","year":"2016","unstructured":"Rojas JC, Karydas A, Bang J et al (2016) Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol 3:216\u2013225. https:\/\/doi.org\/10.1002\/ACN3.290","journal-title":"Ann Clin Transl Neurol"},{"key":"3070_CR63","doi-asserted-by":"publisher","first-page":"E273","DOI":"10.1212\/WNL.0000000000004859","volume":"90","author":"JC Rojas","year":"2018","unstructured":"Rojas JC, Bang J, Lobach IV et al (2018) CSF neurofilament light chain and phosphorylated Tau 181 predict disease progression in PSP. Neurology 90:E273\u2013E281. https:\/\/doi.org\/10.1212\/WNL.0000000000004859","journal-title":"Neurology"},{"key":"3070_CR65","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1046\/J.1471-4159.1996.67052013.X","volume":"67","author":"LE Rosengren","year":"1996","unstructured":"Rosengren LE, Karlsson JE, Karlsson JO et al (1996) Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 67:2013\u20132018. https:\/\/doi.org\/10.1046\/J.1471-4159.1996.67052013.X","journal-title":"J Neurochem"},{"key":"3070_CR66","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jns.2015.03.041","volume":"352","author":"W Sako","year":"2015","unstructured":"Sako W, Murakami N, Izumi Y, Kaji R (2015) Neurofilament light chain level in cerebrospinal fluid can differentiate parkinson\u2019s disease from atypical parkinsonism: evidence from a meta-analysis. J Neurol Sci 352:84\u201387. https:\/\/doi.org\/10.1016\/j.jns.2015.03.041","journal-title":"J Neurol Sci"},{"key":"3070_CR67","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1002\/MDS.28738","volume":"36","author":"I Schulz","year":"2021","unstructured":"Schulz I, Kruse N, Gera RG et al (2021) Systematic assessment of 10 biomarker candidates focusing on \u03b1-Synuclein-Related disorders. Mov Disord 36:2874\u20132887. https:\/\/doi.org\/10.1002\/MDS.28738;CTYPE:STRING:JOURNAL","journal-title":"Mov Disord"},{"key":"3070_CR68","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/J.1468-1331.2006.01452.X","volume":"13","author":"K Seppi","year":"2006","unstructured":"Seppi K, Peralta C, Diem-Zangerl A et al (2006) Placebo-controlled trial of riluzole in multiple system atrophy. Eur J Neurol 13:1146\u20131148. https:\/\/doi.org\/10.1111\/J.1468-1331.2006.01452.X","journal-title":"Eur J Neurol"},{"key":"3070_CR69","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/ANA.26089","volume":"89","author":"W Singer","year":"2021","unstructured":"Singer W, Schmeichel AM, Shahnawaz M et al (2021) Alpha-Synuclein oligomers and neurofilament light chain predict phenoconversion of pure autonomic failure. Ann Neurol 89:1212\u20131220. https:\/\/doi.org\/10.1002\/ANA.26089","journal-title":"Ann Neurol"},{"key":"3070_CR70","doi-asserted-by":"publisher","unstructured":"Singer W, Schmeichel AM, Sletten DM et al (2023) Neurofilament light chain in spinal fluid and plasma in multiple system atrophy \u2013 A Prospective, longitudinal biomarker study. https:\/\/doi.org\/10.21203\/RS.3.RS-3201386\/V1. Res Sq rs.3.rs-3201386","DOI":"10.21203\/RS.3.RS-3201386\/V1"},{"key":"3070_CR71","doi-asserted-by":"publisher","unstructured":"Thebault S, Booth RA, Freedman MS (2020) Blood neurofilament light chain: the neurologist\u2019s troponin? Biomedicines 8:523. https:\/\/doi.org\/10.3390\/BIOMEDICINES8110523","DOI":"10.3390\/BIOMEDICINES8110523"},{"key":"3070_CR72","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.parkreldis.2022.07.007","volume":"102","author":"T Tokutake","year":"2022","unstructured":"Tokutake T, Kasuga K, Tsukie T et al (2022) Clinical correlations of cerebrospinal fluid biomarkers including neuron-glia 2 and neurofilament light chain in patients with multiple system atrophy. Parkinsonism Relat Disord 102:30\u201335. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.07.007","journal-title":"Parkinsonism Relat Disord"},{"key":"3070_CR73","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jim.2004.11.015","volume":"296","author":"WJA Van Geel","year":"2005","unstructured":"Van Geel WJA, Rosengren LE, Verbeek MM (2005) An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid. J Immunol Methods 296:179\u2013185. https:\/\/doi.org\/10.1016\/j.jim.2004.11.015","journal-title":"J Immunol Methods"},{"key":"3070_CR74","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3233\/JAD-190615","volume":"72","author":"SY Wang","year":"2019","unstructured":"Wang SY, Chen W, Xu W et al (2019) Neurofilament light chain in cerebrospinal fluid and blood as a biomarker for neurodegenerative diseases: a systematic review and meta-analysis. J Alzheimer\u2019s Disease 72:1353\u20131361. https:\/\/doi.org\/10.3233\/JAD-190615","journal-title":"J Alzheimer\u2019s Disease"},{"key":"3070_CR76","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/mds.20255","volume":"19","author":"GK Wenning","year":"2004","unstructured":"Wenning GK, Tison F, Seppi K et al (2004) Development and validation of the unified multiple system atrophy rating scale (UMSARS). Mov Disord 19:1391\u20131402. https:\/\/doi.org\/10.1002\/mds.20255","journal-title":"Mov Disord"},{"key":"3070_CR75","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/MDS.29005","volume":"37","author":"GK Wenning","year":"2022","unstructured":"Wenning GK, Stankovic I, Vignatelli L et al (2022) The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov Disord 37:1131\u20131148. https:\/\/doi.org\/10.1002\/MDS.29005","journal-title":"Mov Disord"},{"key":"3070_CR77","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1007\/S00415-018-8893-9","volume":"265","author":"C Wilke","year":"2018","unstructured":"Wilke C, Bender F, Hayer SN et al (2018) Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. J Neurol 265:1618\u20131624. https:\/\/doi.org\/10.1007\/S00415-018-8893-9","journal-title":"J Neurol"},{"key":"3070_CR78","doi-asserted-by":"publisher","unstructured":"Zhang P, Chen J, Cai T et al (2022) Quantitative susceptibility mapping and blood neurofilament light chain differentiate between parkinsonian disorders. Front Aging Neurosci 14. https:\/\/doi.org\/10.3389\/FNAGI.2022.909552","DOI":"10.3389\/FNAGI.2022.909552"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03070-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-03070-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03070-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:51:34Z","timestamp":1779882694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-025-03070-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["3070"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-03070-3","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}